ES2577633T3 - Methods, reagents and kits to detect minimal residual disease - Google Patents
Methods, reagents and kits to detect minimal residual disease Download PDFInfo
- Publication number
- ES2577633T3 ES2577633T3 ES13733084.1 ES2577633T3 ES 2577633 T3 ES2577633 T3 ES 2577633T3 ES 2577633 T3 ES2577633 T3 ES 2577633T3
- Authority
- ES
- Spain
- Prior art keywords
- plasma cells
- kits
- reagents
- methods
- residual disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000007660 Residual Neoplasm Diseases 0.000 title 1
- 239000003153 chemical reaction reagent Substances 0.000 title 1
- 210000004011 Plasma Cells Anatomy 0.000 description 24
- 230000003211 malignant Effects 0.000 description 12
- 102100003279 CD38 Human genes 0.000 description 7
- 101700044948 CD38 Proteins 0.000 description 7
- 210000004027 cells Anatomy 0.000 description 7
- 239000000203 mixture Substances 0.000 description 5
- 206010008943 Chronic leukaemia Diseases 0.000 description 4
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 description 4
- 210000003719 B-Lymphocytes Anatomy 0.000 description 3
- 210000001185 Bone Marrow Anatomy 0.000 description 2
- 102100019450 CD81 Human genes 0.000 description 2
- 101700062651 CD81 Proteins 0.000 description 2
- 102000014961 Protein Precursors Human genes 0.000 description 2
- 108010078762 Protein Precursors Proteins 0.000 description 2
- 238000000149 argon plasma sintering Methods 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- 102100019459 CD27 Human genes 0.000 description 1
- 101700056583 CD27 Proteins 0.000 description 1
- 101700033362 CD28 Proteins 0.000 description 1
- 102100019461 CD28 Human genes 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 102100007544 NCAM1 Human genes 0.000 description 1
- 101700077124 NCAM1 Proteins 0.000 description 1
- 102100005499 PTPRC Human genes 0.000 description 1
- 101700059076 PTPRC Proteins 0.000 description 1
- 102100017729 ROR1 Human genes 0.000 description 1
- 101710036428 ROR1 Proteins 0.000 description 1
- 101700058902 RORA Proteins 0.000 description 1
- 102100017511 SPN Human genes 0.000 description 1
- 101710018229 SPN Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 102000004965 antibodies Human genes 0.000 description 1
- 108090001123 antibodies Proteins 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
Description
ROR1: sobreexpresado sobre células de CLL en comparación con linfocitos B maduros y de transición normales ROR1: overexpressed on CLL cells compared to normal mature and transition B lymphocytes
CD43: sobreexpresado sobre células de CLL en comparación con linfocitos B maduros y de transición normales CD43: overexpressed on CLL cells compared to normal mature and transition B lymphocytes
5 CD81: subexpresado sobre células de CLL en comparación con precursores de célula B y ambos linfocitos B maduros y de transición 5 CD81: underexpressed on CLL cells compared to B cell precursors and both mature and transition B lymphocytes
CD38: subexpresado sobre células de CLL en comparación con precursores de célula B 10 Ejemplo 3. Paneles de anticuerpo y método de diagnóstico para detección de MRD en pacientes con MM/PCD CD38: underexpressed on CLL cells compared to B cell precursors 10 Example 3. Antibody panels and diagnostic method for detection of MRD in patients with MM / PCD
Marcadores para identificación de células de plasma totales en médula ósea: Markers for identification of total plasma cells in bone marrow:
15 Lista de marcadores de identificación: CD38, CD 138 y CD229 15 List of identification markers: CD38, CD 138 and CD229
Cómo utilizarlos: Cualquier combinación de los tres marcadores en cualquier trabajo de posición con fluorocromos; también es posible utilizar cualquier combinación de dos de los tres marcadores o en un subconjunto de casos (no todos) incluso solo uno de los tres marcadores. Las combinaciones preferidas tienen el siguiente orden: 1) How to use them: Any combination of the three markers in any position work with fluorochromes; it is also possible to use any combination of two of the three markers or in a subset of cases (not all) even just one of the three markers. The preferred combinations have the following order: 1)
20 CD138/CD38/CD229; 2) CD138/CD38, 3) CD138/CD229; 4) CD38/CD229; 5) CD138; 6) CD38); 7) CD229. Tenga en cuenta que cualquiera de estos marcadores se puede utilizar individualmente y en combinación en combinación también con dispersión lateral de luz (SSC) o dispersión de luz frontal (FSC) o ambas FSC y SSC para identificar las células de plaama de la médula ósea u otros tipos de muestras (por ejemplo, sangre periférica, biopsia de tejido, fluido espinal). 20 CD138 / CD38 / CD229; 2) CD138 / CD38, 3) CD138 / CD229; 4) CD38 / CD229; 5) CD138; 6) CD38); 7) CD229. Note that any of these markers can be used individually and in combination in combination also with lateral light scattering (SSC) or forward light scattering (FSC) or both FSC and SSC to identify the bone marrow plama cells or other types of samples (for example, peripheral blood, tissue biopsy, spinal fluid).
25 Marcadores para distinguir células de plasma normales vs clonales/malignas: 25 Markers to distinguish normal vs. clonal / malignant plasma cells:
Lista de marcadores y aberración fenotípica más frecuente: List of markers and most frequent phenotypic aberration:
CD38: subexpresado en células de plasma malignas en comparación con células de plasma normales 30 CD27: subexpresado en células de plasma malignas en comparación con células de plasma normales CD38: underexpressed in malignant plasma cells compared to normal plasma cells 30 CD27: under-expressed in malignant plasma cells compared to normal plasma cells
CD45: subexpresado en células de plasma malignas en comparación con células de plasma normales CD45: under-expressed in malignant plasma cells compared to normal plasma cells
35 CD 19: subexpresado (usualmente negativo) en células de plasma malignas en comparación con células de plasma normales 35 CD 19: under-expressed (usually negative) in malignant plasma cells compared to normal plasma cells
CD81: subexpresado en células de plasma malignas en comparación con células de plasma normales CD81: under-expressed in malignant plasma cells compared to normal plasma cells
40 CD56: sobreexpresado en células de plasma malignas en comparación con células de plasma normales 40 CD56: overexpressed in malignant plasma cells compared to normal plasma cells
CD28: sobreexpresado en células de plasma malignas en comparación con células de plasma normales CD28: overexpressed in malignant plasma cells compared to normal plasma cells
CD 117:sobreexpresado en células de plasma malignas en comparación con células de plasma normales CD 117: overexpressed in malignant plasma cells compared to normal plasma cells
45 CyIgk y CyIglambda: expresión a una cualquiera de las otras cadenas ligeras Ig en células de plasma malignas mientras que se muestra una distribución balanceada (la relación de CyIgk/CyIglambda en células de plasma normales usualmente varía entre relaciones 3 y 0.5). CyIgk and CyIglambda: expression to any one of the other Ig light chains in malignant plasma cells while a balanced distribution is shown (the CyIgk / CyIglambda ratio in normal plasma cells usually varies between 3 and 0.5 ratios).
50 SSC: aumento o reducción de intensidad en células de plasma malignas en comparación con células de plasma normales. 50 SSC: increase or decrease in intensity in malignant plasma cells compared to normal plasma cells.
FSC: aumento o reducción de intensidad en células de plasma malignas en comparación con células de plasma normales. 55 FSC: increase or decrease in intensity in malignant plasma cells compared to normal plasma cells. 55
10 10
Claims (1)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261659524P | 2012-06-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2577633T3 true ES2577633T3 (en) | 2016-07-18 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Leemans et al. | The molecular landscape of head and neck cancer | |
| Pløen et al. | Persistence of DNMT 3A mutations at long‐term remission in adult patients with AML | |
| Kervarrec et al. | Diagnostic accuracy of a panel of immunohistochemical and molecular markers to distinguish Merkel cell carcinoma from other neuroendocrine carcinomas | |
| Birkenkamp-Demtröder et al. | Genomic alterations in liquid biopsies from patients with bladder cancer | |
| Battafarano et al. | Large cell neuroendocrine carcinoma: an aggressive form of non-small cell lung cancer | |
| Edgar et al. | Meta-analysis of human methylomes reveals stably methylated sequences surrounding CpG islands associated with high gene expression | |
| Eijsink et al. | Detection of cervical neoplasia by DNA methylation analysis in cervico-vaginal lavages, a feasibility study | |
| Agudelo-Garcia et al. | Glioma cell migration on three-dimensional nanofiber scaffolds is regulated by substrate topography and abolished by inhibition of STAT3 signaling | |
| Hoeller et al. | Epstein-Barr virus–positive diffuse large B-cell lymphoma in elderly patients is rare in Western populations | |
| Ellis et al. | A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer | |
| Barnhill et al. | State of the art, nomenclature, and points of consensus and controversy concerning benign melanocytic lesions: outcome of an international workshop | |
| Miyamoto et al. | Single-cell analysis of circulating tumor cells as a window into tumor heterogeneity | |
| BRPI0718322A2 (en) | METHODS FOR DIAGNOSISING A SUSTAINABILITY FOR CANCER IN A HUMAN INDIVIDUAL, TO IDENTIFY A MARKER FOR USE IN THE ASSESSMENT OF CANCER SUSCETIBILITY, TO GENOTYPE A NUCLEIC ACID SAMPLE TO EVALUATE A UNAUTOUS WATERPROOFER IN A HUMAN RESIDENCE THE PROGNOSIS AND TO MONITOR THE PROGRESS OF A TREATMENT OF AN INDIVIDUAL, KIT TO EVALUATE THE SUSCETIBILITY FOR CANCER IN AN INDIVIDUAL, USE OF AN OLIGONUCLEOTIDE PROBE, MEDIA LEGIBLE BY COMPUTER, AND, DEVICE TO INDICATE A INDICATOR IN AN INDICATOR. . | |
| BR112014009269A2 (en) | diagnosis of fetal chromosomal aneuploidy | |
| Koch et al. | The composition of the microenvironment in follicular lymphoma is associated with the stage of the disease | |
| Jin et al. | Liquid biopsy in uveal melanoma: are we there yet? | |
| WO2012027483A3 (en) | Defining diagnostic and therapeutic targets of conserved free floating fetal dna in maternal circulating blood | |
| Ritter et al. | Reevaluation of established and new criteria in differential diagnosis of Spitz nevus and melanoma | |
| Parra-Grande et al. | Profiling the bladder microbiota in patients with bladder cancer | |
| Xi et al. | Micro-RNA-16 expression in paraffin-embedded specimen correlates with overall survival of T-lymphoblastic lymphoma/leukemia | |
| ES2577633T3 (en) | Methods, reagents and kits to detect minimal residual disease | |
| Kim et al. | DICER1 exons 25 and 26 mutations are rare in common human tumours besides Sertoli-Leydig cell tumour. | |
| BR112012009885A2 (en) | "diagnostic processes for prognosis determination of non-small cell lung cancer" | |
| Moldovan et al. | Genome-wide cell-free DNA termini in patients with cancer | |
| Bhatnagar et al. | The use of molecular genetics to refine prognosis in acute myeloid leukemia |